Funding:

Novartis

Description

Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis. You, or someone you care for, may be able to take part if you/they:
• are a man or woman, 18–65 years of age
• have advancing RMS (where symptoms are getting worse over time)
•  have been treated with an MS therapy (beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide) for at least 3 months.

Participants will be compensated for completing study visits.